Penn Researchers Present Phase II HIV Gene Therapy Trial Data at CROI 2010
Reduced Viral Load set points in subjects treated with Lexgenleucel-T (VRX496TM) following HAART interruption
February 18, 2010 -
Researchers from the University of Pennsylvania School of Medicine presented today the results from an ongoing
Phase I/II open-label clinical trial of Lexgenleucel-T at the 16th Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, CA.
Lexgenleucel-T is a cell and gene therapy product being investigated for the treatment of HIV infection. The current study examined the effect of
Lexgenleucel-T infusions in HIV-1 infected individuals prior to being taken off their antiretroviral treatment (HAART) regimens as part of the
study design's scheduled treatment interruption. In the study, seven of eight evaluable subjects experienced a decrease in viral load set
point and one subject experienced prolonged, complete control of HIV viremia for more than 14 weeks in the absence of HAART. Viral load
set point is the HIV RNA value specific for each infected individual in absence of anti-retroviral drug control. Higher viral load
set point is correlated with more rapid disease progression to AIDS.
"We are excited to see these responses using autologous transfer of CD4+ T lymphocytes genetically modified with VRX496TM,
a HIV-based lentiviral vector encoding for a RNA antisense targeting HIV env . These are subjects who were taken off of their antiretroviral
treatment and are showing a better control of their infection as demonstrated by reduced viral load set points," saidPablo Tebas, M.D ., director
of the Adult AIDS Clinical Trials Unit, who presented the results at CROI. "Further study is needed to see
whether these types of results will translate into a delay in disease progression."
In the current study, several administrations of Lexgenleucel-T, each comprising approximately 1010 autologous CD4+ T cells
transduced ex vivo with VRX496TM, were administered to 17 HIV-1 infected subjects who were fully suppressed on HAART. Each subject received three to six
separate infusions over a period up to 13 weeks. Six weeks after the last infusion, eligible subjects underwent a scheduled treatment interruption to
evaluate timing to HIV RNA recrudescence, changes in viral load set point and changes in CD4 T cell count. Of the 17 subjects who received
infusions, 13 (76%) underwent the scheduled treatment interruption. Eight of these 13 subjects (62%) were evaluable for the efficacy
endpoint. Overall, 7 of 8 (88%) of the evaluable subjects had a decrease in viral load set point ranging from -0.26 to -0.98 Log10.
One subject maintained a complete control of HIV RNA viral load below the limit of detection (50 copies/ml) and a CD4+ cell count
greater than 1200 cells/ÁL for over 14 weeks.
"It is notable that all patients on the protocol had elevated CD4+ counts after treatment with Lexgenleucel-T," said Carl June, M.D ., professor of Pathology and Laboratory
Medicine. "Achieving a complete control of HIV recrudescence following HAART interruption for over 14 weeks is, indeed, remarkable."
Pablo Tebas, MD, David Stein, MD, Gwendolyn Binder, PhD, Larisa Zifchak, RN, Angelo Seda, RN, Jean Boyer, PhD, Faten Aberra, MD, Ronald Collman, MD,
Gerard McGarrity, PhD, Bruce Levine, PhD and Carl June, MD, are all co-authors of this study. The study was funded by the NIH, NIAID. Drs. Tebas,
Zifchak, Boyer, Aberra and Colman are affiliated with the Center for AIDS Research at the University of Pennsylvania, Philadelphia. Drs. Binder,
Levine, June, and Boyer are affiliated with the Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia.
Drs. Stein and Seda are affiliated Jacobi Medical Center, Bronx, New York. Dr. McGarrity is an employee of VIRxSYS Corporation,
Gaithersburg, Maryland. VIRxSYS is the owner of the Lexgenleucel-T therapy. No author on this study other than
Dr. McGarrity is affiliated with VIRxSYS in any capacity beyond their roles as clinical collaborators on this project.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related
missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the University of Pennsylvania School of
Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $3.6 billion
Penn's School of Medicine is currently ranked #3 in U.S. News & World Report's survey of research-oriented medical schools, and is consistently among
the nation's top recipients of funding from the
National Institutes of Health, with $367.2 million awarded in the 2008 fiscal year.
The Hospital of the University of Pennsylvania - the nation's first teaching hospital, recognized as one of the nation's top 10 hospitals by U.S.
News & World Report.
Penn Medicine's patient care facilities include:
Penn Presbyterian Medical Center - named one of the top 100 hospitals for cardiovascular care by Thomson Reuters for six years.
Pennsylvania Hospital - the nation's first hospital, founded in 1751, nationally recognized for excellence in orthopaedics, obstetrics & gynecology,
and behavioral health.
Additional patient care facilities and services include Penn Medicine at Rittenhouse, a Philadelphia campus offering inpatient rehabilitation and
outpatient care in many specialties; as well as a primary care provider network; a faculty practice plan; home care and hospice services; and
several multispecialty outpatient facilities across the Philadelphia region.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2009,
Penn Medicine provided $733.5 million to benefit our community.
Department of Communications
P: (215) 662-2560
F: (215) 349-8312
For the General Public
Source: Penn Medicine - University of Pennsylvania School of Medicine